Introduction: Autologous haemopoietic stem cell transplantation (SCT) is an important treatment modality for patients with acute myeloid leukemia with low and intermediate risk disease. It has served advantages over allogenic transplantation, because it does not need a matched donor, there is no graft versus host disease, there are less complications and a faster immune reconstitution than in the allo-setting. The disadvantage is the lack of the graft versus leukaemia effect.
Introduction
Autologous hematopoietic stem cell transplantation (SCT) is an important therapeutic option in patients with acute myeloid leukemia with no identical sibling for an allogeneic transplantation.
Young patients (age under 60 or 65 years) with goodrisk AML in fi rst CR were recommended to undergo consolidation with high dose chemotherapy ± autologous SCT. Patients with poor-risk AML were recommended to undergo allogeneic SCT [1] .
Several randomized studies, comparing allogeneic transplants in patients with HLA matched siblings to autologous transplantation and to conventional chemotherapy, have shown the superiority of the allogeneic transplant approach to the other approaches, but also the superiority of autografting over conventional chemotherapy. None of the studies have shown the superiority of conventional chemotherapy [2, 3, 4] .
Autologous stem cell transplantation has several advantages and disadvantages in relation to allogeneic stem cell transplantation. Th e faster hematological engraftment, the possibility of applying this treatment to older patients, the lower incidence of complications, the faster immune reconstitution and the absence of graft-versus-host disease are positive factors [5] . Nevertheless, autologous stem cell transplantation is associated with several disadvantages: the lack of "graft versus leukaemia eff ect", ineffi cient number of peripheric stem cells at mobilization and a higher incidence of relapses [6, 7] .
In this study we report the results of 14 patients with acute myeloid leukemia, who underwent autologous peripheral stem cell transplantation.
Material and methods
We retrospectively analyzed 14 patients, transplanted at the Bone Marrow Transplantation Center in Tîrgu Mureș. Th e FAB classifi cation of these acute myeloid leukemia patients was: LAM4 in 10 patients, LAM5 in 3 patients and 1 patient with LAM2. Th e median age at transplantation was 36 years (range 20-55), 9 patients (64%) were males and 5 (36%) were females. Th e median time interval from diagnosis to autologous SCT was 9 months (range .
Th e distribution of cytogenetic categories was defi ned as low risk in 10 patients and intermediate risk in 4 patients.
Autologous stem cell transplantation has been used as the consolidation treatment in 12 patients in fi rst CR1 and in two patients in second CR2. Complete remission was defi ned as normal bone marrow morphology with
Correspondence to: Enikő Kakucs E-mail: enikokakucs@yahoo.com < 5% blasts, resolution of previously abnormal cytogenetics, no evidence of extramedullar leukemia, absolute neutrophil count (ANC) > 1500/μL, and platelets > 140,000/μL. When patients achieved complete remission after induction treatment, we performed mobilization regimens using chemotherapy (Cyclophosphamide 2-4 g/m 2 ) and granulocytic colony stimulating factor (Neupogen 10 μg/kg) followed by peripheral stem cell collection. In 4 patients we had double mobilization of stem cells, the second mobilization was performed only with growth factor, necessary to drive a suffi cient number of hematopoietic stem cells.
In the autologous peripheral stem cell transplantation the following conditioning regimen was administered: Bu (Busulfan 16 mg/kg) to 4 patients; BuCy (Busulfan 16 mg/ kg, Cyclophosphamide 120 mg/kg) to 9 patients and the last patient received BuMel (Busulfan 16 mg/kg, Melphalan 140 mg/m 2 ).
All patients received the harvested stem cell product by infusion. In the post-transplant period for all patients were given G-CSF (Neupogen) to accelerate the engraftment.
Patients were isolated in conventional laminar airfl ow rooms during the period of aplasia. Prophylactic oral antibiotics, antimicotic and antiviral treatment were started to prevent infections. If an infection was suspected, blood samples were taken and wide spectrum antibiotics were initiated. Th e antibiotic treatment was readjusted after microbiological culture results. Each case necessited supportive care with platelet and erythrocyte transfusion, these products were irradiated with 25 Gy.
Results
Peripheral blood stem cells contained a median number of 2.76 × 10 6 /kg CD34+ cells b.w. (range 1.06-6.00). In 9 patients the collected number of stem cells was < 2.5 × 10 6 /kg CD34+, in 5 patients > 2.5 × 10 6 /kg CD34+ cells.
All the patients were transplanted successfully, all of them achieved a sustained neutrophil count (>0.5 G/L), median time 11 days (9-15) and platelet count (> 20 G/L) median time 14 days (10-19) after transplantation.
Between patients with CD34+cell dose < 2.5 × 10 6 /kg (n = 9) or > 2.5 × 10 6 /kg (n = 5) we observed signifi cant diff erences regarding neutrophil engraftment: 11 days (range 9-11) and 13 days (range [11] [12] [13] [14] [15] , and the same difference was present regarding platelet engraftment: 12 days (range 10-13) and 15 days (range 14-19). Th is short duration of neutropenia contributed to the low morbidity. Infective complications occurred in 45% of the patients. Transfusion requirements were low, patients requiring a median of 3 units of red blood cells and 5 platelet transfusions.
Th e main extra-hematological toxicities were mucositis (grade 1-2), diarrhea, nausea, cardiac arrhythmia, hypertension, hepatic and cardiac toxicity.
From the 14 patients who received autologous stem cell transplantation there were 2 deaths within 100 days of the transplant: 1 with cardiac toxicity at day + 12 and 1 with severe viral infection and acute infl ammatory demyelinating polyradiculoneuropathy.
Six of the patients remained more than fi ve years in complete remission after autologous stem cell transplantation. One of the patients achieved complete remission and returned to his everyday work and activities.
Leukemia progression was observed in 5 patients, 3 of them died within 1 year of transplantation. Two cases had relapsed after PBSC transplantation, one of them after 10 months, the second after three months. At the moment, they receive chemotherapy and allogeneic transplantation from unrelated donors will be performed.
Discussion
In our study we analyzed the role of autologous SCT in patients with AML with low and intermediate risk who do not have an identical sibling donor.
Numerous studies have demonstrated that rapid engraftment depends on the number of CD34+ cells [8, 9] . We observed that infusion of CD34+ cells > 2.5 × 10 6 /kg is associated with faster neutrophil and platelet engraftment.
Th e conditioning regimen seemed to be well tolerated, without impairment of organ function or relevant extrahematological adverse event.
Irrespective of the choice of ASCT or chemotherapy, relapse of leukemia remains the predominant cause of treatment failure [10, 11] . Earlier studies reported the results of auto-SCT for AML patients in CR1 with favorable cytogenetics were better than those observed with conventional chemotherapy [12, 13] . In our study the higher relapse was associated in patients with intermediate-risk cytogenetics. In this group of patients allo-SCT emerged as the treatment of choice [14] .
In multivariate analysis, the age of patients at transplant emerged as an important prognostic factor for overall survival and disease-free survival. Older patients more often have poor-risk leukemic characteristics, chemoresistant profi le and severe comorbidities than younger patients, and tolerate prolonged aplastic periods and intensive therapy less well [15, 16] . We were not able to evaluate this factor since a signifi cant number of patients were not transplanted.
